Market closedNon-fractional

Omeros/OMER

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Omeros

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Ticker

OMER

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Seattle, United States

Employees

198

Omeros Metrics

BasicAdvanced
$224M
Market cap
-
P/E ratio
-$1.96
EPS
1.36
Beta
-
Dividend rate
$224M
1.36
4.757
4.03
-627.63
-661.939
-5.39%
-21.03%
2,185.05%
-3.14
-3.14
-1.677
-363.92%
-6.96%

What the Analysts think about Omeros

Analyst Ratings

Majority rating from 3 analysts.
Hold

Omeros Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$37M
312.22%
Profit margin
0.00%
NaN%

Omeros Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 8.50%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.59
-$0.60
-$0.15
-$0.63
-
Expected
-$0.57
-$0.62
-$0.56
-$0.58
-$0.70
Surprise
3.75%
-2.49%
-72.97%
8.50%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Omeros stock?

Omeros (OMER) has a market cap of $224M as of July 06, 2024.

What is the P/E ratio for Omeros stock?

The price to earnings (P/E) ratio for Omeros (OMER) stock is 0 as of July 06, 2024.

Does Omeros stock pay dividends?

No, Omeros (OMER) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Omeros dividend payment date?

Omeros (OMER) stock does not pay dividends to its shareholders.

What is the beta indicator for Omeros?

Omeros (OMER) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Omeros stock

Buy or sell Omeros stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing